

DAY1 / THURSDAY DECEMBER 8, 2022

TIME	PROGRAM	
8:35-9:00	Session 1: Opening Lecture: Epidemiology of prostate cancer in Asian countries	Takashi Fukagai [Japan]
	Epidemiology of prostate cancer in Asian countries	Takahiro Kimura [Japan]
9:00-10:00	Session 2: Current Status of PSA Screening in Asian Countries	Koichiro Akakura [Japan], Byung Ha Chung [Korea]
	Current Status of PSA Screening in China	Dingwei Ye [China]
	Current status of PSA screening in KOREA	Jae Young Joung [Korea]
	Prostate Cancer Screening in Indonesia	Lukman Hakim [Indonesia]
10:00-10:40	Session 3: Topics of Active Surveillance and PSA screening in Japan	Kazuhiro Suzuki [Japan]
	PSA screening in Japan	Kazuto Ito [Japan]
	Active Surveillance for early Prostate Cancer—PRIAS-JAPAN—	Mikio Sugimoto [Japan]
	Co-sponsored by Takeda Pharmaceutical Company Limited	
10:50-11:50	Session 4: Treatment for Localized Prostate Cancer 1 Radiation therapy	Jun Hyuk Hong [Korea], Osamu Ogawa [Japan]
	IMRT for prostate cancer	John Lederer [USA]
	Permanent seed implantation prostate brachytherapy in Japan	Shiro Saito [Japan]
	Experience of Proton Beam Therapy for Localized Prostate cancer in Tsukuba University	Hiroyuki Nishiyama [Japan]
12:05-12:55	Session 5: Luncheon Seminar: Topics of RARP	Yukihiro Kondo [Japan], Tomohiko Ichikawa [Japan]
	Key anatomical structures and points of surgical procedure in robot-assisted radical prostatectomy—Achieving early recovery of urinary continence—	Yuta Yamada [Japan]
	Usefulness of Retzius-sparing technique to prevent postoperative urinary incontinence after robot-assisted radical prostatectomy (RARP)	Atsushi Okada [Japan]
	Co-sponsored by Intuitive Surgical	
13:10-13:50	Session 6: Treatment for Localized Prostate Cancer 2 RARP: New Platform	Levent Türkeri [Turkey], Yasutomo Nasu [Japan]
	Robot-assisted radical prostatectomy using hinotori	Nobuyuki Hinata [Japan]
	Robotic Prostatectomy 2022: SP Retzius-Sparing & Perineal.	Koon Ho Rha [Korea]
13:50-14:30	Session 7: Treatment for Localized Prostate Cancer 3 RARP: Tips and Tricks	Dennis Serrano [Philippines], Takeshi Shichiyo [Japan]
	Application of dehydrated human amnion/chorion membrane on patients undergoing Robotic Assisted Radical Prostatectomy (RARP)	Yen Chuan Ou [Taiwan]
	Robot Assisted Radical Prostatectomy(RARP): Techniques to Preserve Potency and Continence	Choung-Soo Kim [Korea]

14:40-15:20	Session 8: Target biopsy and Focal therapy	Go Kimura [Japan], Seong Il Seo [Korea]
	Robot-assisted Magnetic Resonance Imaging-ultrasound Fusion Transperineal Targeted Biopsy	Henry Ho [Singapore]
	Focal therapy with high-intensity focused ultrasound for the localized prostate cancer based on magnetic resonance imaging-transrectal ultrasound fusion image-guided target biopsy in Japan	Sunao Shoji [Japan]
15:20-16:00	Session 9: Ablation therapy for prostate cancer	Robert G. Carlile [USA], Yoshiyuki Kakehi [Japan]
	Irreversible electroporation (IRE) for prostate cancer using PSMA PET-CT	Ji Youl Lee [Korea]
	The routine use of high intensity focused ultrasound for the treatment of localized prostate cancer	Po Hui Chiang [Taiwan]
16:15-16:55	Session 10: Topics of the managements of mHSPC	Mototsugu Oya [Japan]
	Current status and future perspectives of the managements of metastatic prostate cancer	Kazutoshi Fujita [Japan]
	Co-sponsored by Astellas Pharma Inc.	
17:05-18:35	Moderated Poster Presentation 1	Kazuhiko Oshinomi [Japan], Jacob ST Pang [Taiwan], Thomas S Namiki [USA]
MP1-1	A mitochondria-targeted drug induces apoptosis in prostate cancer xenografts	Seiji Arai [Japan]
MP1-2	Hyperforin Induces Extrinsic/Intrinsic Apoptosis Signaling and Inhibits NF- κ B for Metastasis Suppression in Prostate Cancer Cells	Cheng-Hsi Liao [Taiwan]
MP1-3	Combination therapy with novel androgen receptor antagonists and statin for castration-resistant prostate cancer	Yoshitaka Sekine [Japan]
MP1-4	Lipopolysaccharide from dysbiotic gut microbiome promotes prostate cancer growth through histamine H1 receptor signaling	Kazutoshi Fujita [Japan]
MP1-5	GDF15 propeptide is a novel and useful biomarker for bone metastases in prostate cancer	Gaku Yamamichi [Japan]
MP1-6	Withdrawn	
MP1-7	Is 12 Systemic Cores in Transperineal Biopsy Sufficient for Detecting Clinically Significant Prostate Cancer?	Chang Eil Yoon [Korea]
MP1-8	The Impact of mpMRI on Treatment Strategy for Incidental Prostate Cancer after HoLEP	Chung Un Lee [Korea]
MP1-9	Clinicopathological analysis of prostate cancer with lymph node metastasis in the prostatic anterior fat pad	Junichi Ikeda [Japan]
MP1-10	Robotic-Assisted Simple Prostatectomy using the da Vinci SP system, pilot study	ByungHoon Kim [Korea]
MP1-11	Early outcomes of Single port robotic radical prostatectomy: 1 year followed up	Seokhwan Bang [Korea]
MP1-12	Comparison of longitudinal health-related QOL outcomes between anterior and posterior approaches to robot-assisted radical prostatectomy	Naoya Nagasaki [Japan]
MP1-13	Novel Nomogram Predicting Biochemical Recurrence-Free Survival After Radical Prostatectomy	leandro blas [Japan]
MP1-14	Carbon-ion radiotherapy for high-risk prostate cancer in Gunma University Heavy Ion Medical Center	Hiroshi Matsui [Japan]
MP1-15	Salvage low-dose rate brachytherapy for local recurrence of prostate cancer after radical radiotherapy	Takahiro Nakamoto [Japan]

DAY2 / FRIDAY DECEMBER 9, 2022

TIME	PROGRAM	
8:30-9:10	Session 11: Topics of RCC	Tohru Nakagawa [Japan]
	Practice of clinical approaches to first-line treatment for metastatic renal cell carcinoma.~A new era of immune checkpoint inhibitors (ICI) -based combination therapy~	Jun Morita [Japan]
	Co-sponsored by Pfizer	
9:10-9:40	Session 12: Medication for BPH & LUTS	Hiroyuki Nishiyama [Japan]
	Treatment strategy for OAB with BPH	Naoya Masumori [Japan]
	Co-sponsored by KYORIN Pharmaceutical Co., Ltd.	
9:50-10:50	Session 13: New Surgical Techniques & New treatment Strategies for BPH	Bannakij Lojanapiwat [Thailand], Satoru Takahashi [Japan]
	Water Vapor Therapy for Benign Prostatic Hyperplasia—the Hong Kong Experience	Anthony C.F. Ng [Hong Kong]
	Prostatic Urethral Lift (Urolift) for the treatment of LUTS in 2022	Henry Woo [Australia]
	Effects of Transoral Robotic Surgery (TORS)- Obstructive Sleep Apnea (OSA) Surgery on Lower Urinary Tract Symptoms in Male Patients with OSA/Hypopnea Syndrome	Yao-Chi Chuang [Taiwan]
11:00-12:00	Moderated Poster Presentation 2	Kyung Seop Lee [Korea], Robert G. Carlile [USA]
MP2-1	Changes of resistance indices after medication in benign prostatic hyperplasia: a prospective study	Kyung Seop Lee [Korea]
MP2-2	The Association between Human Gut Microbiota and Benign Prostatic Hyperplasia	Kentaro Takezawa [Japan]
MP2-3	PSA doubling time predicts the efficiency of site-directed therapy for non-metastatic or oligometastatic CRPC	Taketo Kawai [Japan]
MP2-4	Switching to darolutamide for MOCRPC resistant to enzalutamide or apalutamide	Saizo Fujimoto [Japan]
MP2-5	Efficacy and Safety of Enzalutamide and Apalutamide in the Treatment of Patients with nmCRPC: A retrospective analysis	Shuhei Hara [Japan]
MP2-6	How I recruit the suitable nmCRPC patients for taking insurance-reimbursed Darolutamide in Taiwan	Kuan-Chou Chen [Taiwan]
MP2-7	Cisplatin and Etoposide for treatment-related Neuroendocrine Prostate Cancer: avorable early Response with short Duration	Yuto Tsubonuma [Japan]
MP2-8	Biology and usefulness of [-2] proPSA as a prognostic marker in CRPC patients	Yoshiyuki Miyazawa [Japan]
MP2-9	The Effects of Personal and Family Cancer History on the Diagnosis of Prostate Cancer in a Multi-Institutional Prostate Biopsy Registry	Jeong Woo Yoo [Korea]
MP2-10	Withdrawn	
12:15-13:15	Session 14: Luncheon Seminar Topics of MOCRPC	Hideki Sakai [Japan]
	Non-metastatic CRPC or “Early” CRPC? Challenges in CRPC treatment in the era of next-generation imaging.	Shusuke Akamatsu [Japan]

Changes in treatment landscape for non-metastatic CRPC: what has novel hormonal therapy brought about?		
Kohei Hashimoto [Japan]		
Co-sponsored by Bayer Yakuhin, Ltd./Nippon Kayaku Co., Ltd.		
13:30-14:00	Session 15: Topics of Bone Scan	Takahiro Kimura [Japan]
Importance of Imaging Follow-up for Advanced Prostate Cancer		
Kazuki Sudo [Japan]		
Co-sponsored by Nihon Medi-physics Co., Ltd.		
14:00-14:40	Session 16: Treatment strategy for mCSPC	Hirotsugu Uemura [Japan]
Treatment strategy for mCSPC		
Declan G. Murphy [Australia]		
Co-sponsored by Janssen Pharmaceutical K.K./Nippon Shinyaku Co., Ltd.		
14:50-15:30	Session 17: Topics of BRCA &CRPC	Naohiro Fujimoto [Japan]
The role of olaparib in the treatment of mCRPC		
Hiroshi Kitamura [Japan]		
Co-sponsored by AstraZeneca		
15:30-16:20	Session 18: What is the best treatment sequence of metastatic Pca?	Hiroyoshi Suzuki [Japan], Edmund Chiong [Singapore]
Panelist: Jae il Chung [Korea], Teng Aik Ong [Malaysia], Hiroshi Kitamura [Japan], Kuan Chou Chen [Taiwan]		
Metastatic Prostate Cancer Treatment—Considerations in Asia		
Edmund Chiong [Singapore]		
16:20-16:50	Session 19: Advance in PSMA theranostics	Norio Nonomura [Japan]
A single dose of novel PSMA-targeting radiopharmaceutical agent [¹⁷⁷ Lu] Lutetadipep for patients with metastatic castration-resistant prostate cancer: Phase I clinical trial		
Ji Youl Lee [Korea]		
Co-sponsored by Future Chem		
17:00-18:15	APPS & ACaP Joint Symposium (7th A-Cap meeting)	
Opening Remarks		
Haruki Kume [Japan]		
Special Lecture		
Takashi Fukagai [Japan]		
The utilization of the Japan Study Group of Prostate Cancer registry data		
Masaki Shiota [Japan]		
Changes in the trends of initial treatment for newly diagnosed prostate cancer in Japan: A nationwide multi-institutional study		
Taketo Kawai [Japan]		
Reports from participating countries		
Tohru Nakagawa [Japan]		
1. Malaysia		
Teng Aik Ong [Malaysia]		
2. Turkey		
Levent Turkeri [Turkey]		
3. Japan		
Mizuki Onozawa [Japan]		
Closing Remarks		
Teng Aik Ong [Malaysia]		
18:30-19:00	Best Poster Award at Foyer	Hidefumi Kinoshita [Japan]

DAY3 / SATURDAY DECEMBER 10, 2022

TIME	PROGRAM	
APPS & Prostate Cancer Symposium joint session		
8:30-9:00	Session 20: Liquid Biopsy	Kazuhiro Suzuki [Japan]
	Liquid Biopsy for Prostate Cancer	Yeong-Shiau Pu [Taiwan]
9:00-10:00	Session 21: Topics of New Diagnostic Methods p2PSA	Rainy Umbas [Indonesia], Yoshihiko Hirao [Japan]
	Current update on prostate health index (<i>phi</i>) in Japan	Kazuto Ito [Japan]
	Effectiveness of [-2]proPSA measurement in the diagnosis of significant prostate cancer compared to MRI and PSA	Hiroji Uemura [Japan]
	Co-sponsored by Beckman Coulter	